115 related articles for article (PubMed ID: 37180696)
1. Ubiquitin-proteasome system-based signature to predict the prognosis and drug sensitivity of hepatocellular carcinoma.
Zhang J; Liu L; Wang Z; Hou M; Dong Z; Yu J; Sun R; Cui G
Front Pharmacol; 2023; 14():1172908. PubMed ID: 37180696
[No Abstract] [Full Text] [Related]
2. Identification and Validation of Ubiquitin-Specific Proteases as a Novel Prognostic Signature for Hepatocellular Carcinoma.
Ni W; Bian S; Zhu M; Song Q; Zhang J; Xiao M; Zheng W
Front Oncol; 2021; 11():629327. PubMed ID: 33718205
[TBL] [Abstract][Full Text] [Related]
3. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
4. Systematic Characterization of Novel Immune Gene Signatures Predicts Prognostic Factors in Hepatocellular Carcinoma.
Xu D; Wang Y; Wu J; Zhang Y; Liu Z; Chen Y; Zheng J
Front Cell Dev Biol; 2021; 9():686664. PubMed ID: 34631695
[No Abstract] [Full Text] [Related]
5. A novel prognostic model based on immunogenic cell death-related genes for improved risk stratification in hepatocellular carcinoma patients.
Liu T; Chen X; Peng B; Liang C; Zhang H; Wang S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10255-10267. PubMed ID: 37269346
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
Wang L; Wang L; He P
Front Genet; 2022; 13():1064432. PubMed ID: 36568383
[No Abstract] [Full Text] [Related]
7. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
8. Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma.
Shen B; Zhang G; Liu Y; Wang J; Jiang J
Genes (Basel); 2022 Oct; 13(10):. PubMed ID: 36292719
[TBL] [Abstract][Full Text] [Related]
9. [Construction of a prognostic model for hepatocellular carcinoma based on pyroptosis-related genes].
Rong HC; Zhao WF; Zheng N; Guo ZH; Wang YW; Huang XP
Zhonghua Gan Zang Bing Za Zhi; 2023 May; 31(5):509-517. PubMed ID: 37365028
[No Abstract] [Full Text] [Related]
10. Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
Tang P; Qu W; Wang T; Liu M; Wu D; Tan L; Zhou H
Front Genet; 2021; 12():785185. PubMed ID: 34917132
[No Abstract] [Full Text] [Related]
11. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
12. Four-gene signature predicting overall survival and immune infiltration in hepatocellular carcinoma by bioinformatics analysis with RT‒qPCR validation.
Guan R; Zou J; Mei J; Deng M; Guo R
BMC Cancer; 2022 Jul; 22(1):830. PubMed ID: 35907846
[TBL] [Abstract][Full Text] [Related]
13. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
Li Y; Zeng X
Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
[No Abstract] [Full Text] [Related]
14. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer.
Chen X; Ren C; Zhou Z; Chen J; Fan X; Li X; Chen J; Zhu J
J Gene Med; 2024 Jan; 26(1):e3584. PubMed ID: 37605934
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of ubiquitin-proteasome system related genes as a prognostic signature for papillary renal cell carcinoma.
Zhang X; Liu X; Xiong R; An HX
Aging (Albany NY); 2022 Nov; 14(23):9599-9616. PubMed ID: 36385010
[TBL] [Abstract][Full Text] [Related]
16. Prognostic model for hepatocellular carcinoma based on anoikis-related genes: immune landscape analysis and prediction of drug sensitivity.
Zhang D; Liu S; Wu Q; Ma Y; Zhou S; Liu Z; Sun W; Lu Z
Front Med (Lausanne); 2023; 10():1232814. PubMed ID: 37502362
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis to identify the neurotransmitter receptor-related genes as prognostic and therapeutic biomarkers in hepatocellular carcinoma.
Wang X; Li Y; Shi Y; Luo J; Zhang Y; Pan Z; Wu F; Tian J; Yu W
Front Cell Dev Biol; 2022; 10():887076. PubMed ID: 35990607
[No Abstract] [Full Text] [Related]
20. A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients.
Wang Z; Zhang N; Lv J; Ma C; Gu J; Du Y; Qiu Y; Zhang Z; Li M; Jiang Y; Zhao J; Du H; Zhang Z; Lu W; Zhang Y
Biomed Res Int; 2020; 2020():4037639. PubMed ID: 33163533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
